Article

HER2; p53 Co-mutated Cancers Show Increased Histone Acetylation and are Sensitive to Neratinib plus Trastuzumab Deruxtecan

2025-07-10

Abstract excerpt

In metastatic breast cancer, HER2 -activating mutations often co-occur with TP53 mutations, a combination linked to poor response to neratinib and worse prognosis. To model this clinical challenge, we bred HER2 V777L transgenic mice with two TP53 mutant alleles: TP53 R172H (the murine homolog of human TP53 R175H) and TP53 fl/fl , which mimics p53 truncations common in human tumors. TP53 mutations accelerat...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e8e00621-4413-5e64-9392-9ec47821414d
DOI: 10.1101/2025.07.06.663368

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

HER2; p53 Co-mutated Cancers Show Increased Histone Acetylation and are Sensitive to Neratinib plus Trastuzumab DeruxtecanDOI 10.1101/2025.07.06.663368Read

Breast cancer mutations HER2 <sup>V777L</sup> and PIK3CA <sup>H1047R</sup> activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistanceSemantic proximity Read

Breast Cancer Mutations HER2V777L and PIK3CAH1047R Activate the p21-CDK4/6-Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance.Semantic proximity Read

p53R172H and p53R245W Hotspot Mutations Drive Distinct Transcriptomes in Mouse Mammary Tumors Through a Convergent Transcriptional Mediator.Semantic proximity Read

Attenuation of p53 mutant as an approach for treatment Her2-positive cancerSemantic proximity Read

Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast CancerSemantic proximity Read

Targeting of MARK2, but not other MARKs, suppresses TNBC progression by inhibition of the mutant p53-driven signaling pathway.Semantic proximity Read

Mutant p53 Amplifies Epidermal Growth Factor Receptor Family Signaling to Promote Mammary Tumorigenesis.Semantic proximity Read

Mutant p53 gain of function induces HER2 over-expression in cancer cellsSemantic proximity Read

Correlating p53 immunostaining patterns with somatic TP53 mutation and functional properties of mutant p53 in triple-negative breast cancerSemantic proximity Read

Dual HER2/HER3 Targeting with Antibody-Drug Conjugates Reveals a Novel Therapeutic Strategy for HER2-Mutant Lobular Breast CancerSemantic proximity Read

Early onset HER2-positive breast cancer is associated with germline TP53 mutations.Semantic proximity Read

Mutant p53 Directs PARP to Regulate Replication Stress and Drive Breast Cancer MetastasisSemantic proximity Read